<DOC>
	<DOCNO>NCT01379209</DOCNO>
	<brief_summary>The clinical trial Phase 1/2a , open-label , multi-center , dose-escalation study evaluate safety , tolerability pharmacokinetic profile RGI-2001 patient undergo AHSCT , radiation non-radiation myeloablative preparative treatment . The study separate two part ; dose escalation phase ass safety , follow large expansion phase evaluate pharmacologic effect either Maximum Tolerated Dose , Maximum Feasible Dose optimal pharmacologically active dose RGI-2001 . The initial dose escalation safety portion study ( Part 1 ) include high risk patient limit unrelated donor transplant . After safety establish part 1 study , second portion study expand enrollment criterion allow transplantation either relate unrelated donor . This study endeavor identify dose range RGI-2001 acceptable safety profile , biologic activity observe , guide possible dose level utilize later phase study base biological activity .</brief_summary>
	<brief_title>Intravenous Administration RGI-2001 Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation ( AHSCT )</brief_title>
	<detailed_description>The clinical trial Phase 1/2a , open-label , multi-center , dose-escalation study evaluate safety , tolerability pharmacokinetic profile RGI-2001 patient undergo AHSCT , radiation non-radiation myeloablative preparative treatment . In Part 1 ( Phase 1 : Dose Escalation Phase ) , patient receive single intravenous administration RGI-2001 approximately 30 minute completion transplant ( either allogeneic PBSCs allogenic bone marrow transplantation ( unmodified ) ) dosage base upon assign treatment cohort . Eligible patient enrol five seven center United States . Patients undergoing AHSCT enrol sequential group dose-escalating fashion determine safety , tolerability , pharmacokinetic profile , MTD MFD RGI-2001 . It anticipate six dose level evaluate Part 1 , option additional cohort ( Cohort 7 ) MTD reach pharmacodynamic marker suggest high dos warrant . In Part 2 ( Expansion Phase ) , one dose MTD MFD select base potential correlation GvHD biological activity ass safety biologic activity . Approximately 30 patient undergo either allogeneic PBSCs allogenic bone marrow transplantation ( unmodified ) enrol Part 2 study . Patients monitor safety 29 day transplant procedure . All patient follow 100 day follow transplant procedure incidence acute GvHD , accord Modified Keystone Criteria grade acute GvHD ( Przepiorka D , et al )</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Subject hematological malignancy aplastic anemia ( AA ) undergo first allogeneic transplant procedure . 2 . Meet one follow underlie disease criterion : . Acute myelogenous leukemia ( AML ) . First subsequent morphologic remission b . Acute lymphoblastic leukemia ( ALL ) . First subsequent morphologic remission c. Chronic myelogenous leukemia ( CML ) . Chronic phase ; ii . Accelerated phase d. Multiple Myeloma ( MM ) . Not 20 % plasma cell bone marrow e. Myelodysplastic syndrome ( MDS ) , include chronic myelomonocytic leukemia ( CMML ) , receive least one previous induction regimen &lt; 10 % blast f. Myeloproliferative disorder ( MPD ) , include ; i. myeloid metaplasia , ii . myelofibrosis g. NonHodgkin 's Lymphoma ( NHL ) i. Highrisk NHL first remission ; ii . Relapsed refractory NHL h. Hodgkin 's lymphoma ( HL ) beyond first remission i. Aplastic anemia ( AA ) 3 . Male female , age ≥18 year age 4 . Reasonable expectation survival least 3 month , transplant procedure successful 5 . Eastern Cooperative Oncology Group ( ECOG ) status 02 Karnofsky Performance Status ( KPS ) &gt; 60 6 . Transplant Donor 1 . Part 1 ( Phase 1 : Dose Escalation Phase ) : Unrelated transplant donor 1 HLA allele antigen mismatch , define loci A , B , C DR ( note : DQ exclude ) 2 . Part 2 ( Phase 2a : Expansion Phase ) : Related unrelated transplant donor , 1 HLA allele antigen mismatch , define loci A , B , C DR ( note : DQ exclude ) . 7 . Source allograft 1 . Part 1 ( Phase 1 : Dose Escalation Phase ) : Unmodified ( nonmanipulated ) bone marrow , mobilize peripheral blood stem cell ( PBSC ) transplant , use GCSF mobilize agent . 2 . Part 2 : ( Phase 2a : Expansion Phase ) Unmodified ( nonmanipulated ) bone marrow , mobilize peripheral blood stem cell ( PBSC ) transplant , use GCSF mobilize agent . 8 . Antigraftversushost disease ( GvHD ) prophylaxis : A calcineurin inhibitor [ either tacrolimus ( FK506 ) cyclosporin A ) ] , combination either methotrexate ( MTX ) , mycophenolate mofetil ( MMF ) sirolimus ( RAPA ) dose per institutional protocol 9 . Adequate hepatic function , bilirubin exceed upper limit normal ( except attribute Gilbert 's Disease ) , AST ALT less 1.5 time upper limit normal 10 . No clinically significant cardiac conduction disorder screen ECG 11 . Serum creatinine ≤ 2.0 mg/dL 12 . Female patient childbearing potential must negative serum pregnancy test prior enrollment must agree use dual method contraception 30 day study drug administration . Approved method contraception include , IUD spermicide , female condom spermicide , diaphragm spermicide , cervical cap spermicide , use condom spermicide sexual partner sterile sexual partner . 13 . If male , subject must sterile willing use approve method contraception time Informed Consent 30 day study drug treatment . Males must willing refrain sperm donation within 30 day study drug treatment . 14 . No clinically significant acute chronic medical condition opinion investigator interfere study participation 15 . No clinically significant laboratory abnormality determine Principal Investigator , consultation Sponsor 's Medical Monitor 16 . No active infection 17 . Have sign write informed consent undergo study related procedure willing comply study procedures 1 . Female subject pregnant lactate 2 . Subjects undergo nonablative nonmyeloablative transplant 3 . AML ALL patient relapse ( &gt; 5 % blast ) define primary refractory 4 . Blast crisis CML 5 . Radiation , chemotherapy , immunotherapy previous 3 week , unrelated transplant procedure 6 . Subjects , judgment Investigator recover effect previous therapy 7 . Subject undergo cord blood transplantation 8 . Procedures intend deplete regulatory Tcells donor transplant material 9 . Known suspected HIV infection 10 . Active hepatitis A , B , C infection recipient donor 11 . Uncontrolled active infection require IV antibiotic recipient donor 12 . Major surgery within 1 month Day 0 13 . Participation investigational study within 1 month prior Day 0 14 . Prior treatment antiCD3 antibodies 15 . Treatment antiCD20 antibody antithymocyte globulin ( ATG ) within 3 month AHSCT procedure ( i.e . infusion transplant material RGI2001 ) . 16 . Vaccination within precede 2 week prior plan dose RGI2001 17 . Planned vaccination within 2 month study drug administration 18 . Known history cardiac dysfunction ( e.g . &lt; 50 % ejection fraction ) , ischemia , conduction abnormality , myocardial infarction previous six month 19 . Cardiac pacemaker automatic implantable cardioverterdefibrillator 20 . Marked baseline prolongation QT/QTc interval ( e.g. , repeated demonstration QTc interval &gt; 450 m 21 . Congenital long QT syndrome family history long QT syndrome 22 . History additional risk factor torsades de pointes ( TdP ) ( e.g. , heart failure , hypokalemia ) 23 . Bundle branch block 24 . Connective tissue/rheumatologic disorder 25 . History autoimmune disease 26 . History solid tumor , exclude nonmelanoma skin cervical carcinoma curative resection , within precede 5 year 27 . Uncontrolled diabetes 28 . Prior allogeneic hematopoietic stem cell transplantation 29 . Any prior organ transplant 30 . Psychiatric addictive disorder preclude obtain reliable inform consent 31 . Any condition , opinion investigator , render subject unsuitable study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AHSCT</keyword>
	<keyword>Bone Marrow Transplant</keyword>
	<keyword>Leukemia</keyword>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>hematological malignancy</keyword>
	<keyword>Graft-versus-host-disease</keyword>
	<keyword>GvHD</keyword>
	<keyword>Hematopoietic Stem Cell Transplantation</keyword>
	<keyword>Stem Cell</keyword>
	<keyword>Transplantation</keyword>
</DOC>